Company Monitoring Page for Orexigen

latest headlines for company on cafepharma

Orexigen’s Weight-Loss Roller Coaster to End With a Bankruptcy Sale
Xconomy
Mon, 03/12/18 - 09:47 am
Tags:
Orexigen, bankruptcy, Contrave
Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns
Endpoints
Tue, 10/17/17 - 09:50 am
Tags:
Orexigen, Contrave, M&A
Orexigen - Contrave Sales Present Troubling Data
Seeking Alpha
Tue, 06/21/16 - 11:21 am
Tags:
Orexigen, Contrave, obesity
Orexigen struggles to stay afloat as obesity market stagnates
BioPharma Dive
Thu, 05/19/16 - 09:43 am
Tags:
Orexigen, obesity, Contrave, Vivus, Qsymia, Takeda
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Mon, 05/16/16 - 09:32 pm
Tags:
Arena Pharmaceuticals, obesity, Orexigen, Belviq, Eisai, Vivus, Novo Nordisk, Qsymia, Victoza
Orexigen Therapeutics posts 1st-quarter loss of $22.3 million
Yahoo/AP
Wed, 05/4/16 - 06:46 pm
Tags:
Orexigen, earnings
Orexigen Pulls The Plug On Post-Marketing Cardiovascular Trial
Seeking Alpha
Sat, 04/16/16 - 04:06 pm
Tags:
Orexigen, Contrave
Orexigen: Contrave Sales Flatten Out At End Of Q1
Seeking Alpha
Mon, 04/11/16 - 09:58 am
Tags:
Orexigen, Contrave, obesity, Novo Nordisk, Vivus, Arena Pharmaceuticals
Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant
Yahoo/Reuters
Tue, 03/15/16 - 09:32 am
Tags:
Orexigen, obesity, Contrave, Takeda, Valeant Pharmaceuticals, M&A
Orexigen takes another body blow from ill-fated Contrave trial
Fierce Pharma
Wed, 03/9/16 - 03:40 pm
Tags:
Orexigen, Contrave, obesity, Takeda, clinical trials
The Next 6 Months Are Critical For Orexigen
Seeking Alpha
Wed, 03/2/16 - 10:51 am
Tags:
Orexigen
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Fierce Pharma Marketing
Tue, 03/1/16 - 10:56 pm
Tags:
obesity, Vivus, Orexigen, Contrave, Qsymia, Takeda
Belviq Sales Close Out 2015 With A Slump
Seeking Alpha
Sat, 01/9/16 - 10:39 am
Tags:
Belviq, Arena Pharmaceuticals, obesity, Vivus, Orexigen
Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says
Fierce Pharma Marketing
Mon, 11/9/15 - 03:38 pm
Tags:
Takeda, Contrave, drug reps, Orexigen
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Wed, 09/30/15 - 07:41 pm
Tags:
Orexigen, Immunomedics, Celldex Therapeutics, Arena Pharmaceuticals, Theravance, Karyopharm, Raptor Pharmaceutical, Verastem, Tetraphase, Xoma
Contrave script growth snags, despite Takeda's 900-strong salesforce
Fierce Pharma Marketing
Tue, 09/29/15 - 09:16 am
Tags:
Contrave, Takeda, Orexigen, obesity
Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?
Motley Fool
Sat, 09/19/15 - 09:14 am
Tags:
Orexigen, Europe, drug launches, obesity, Mysimba, Contrave
Orexigen Therapeutics reports second-quarter loss, misses expectations
Yahoo/AP
Thu, 08/6/15 - 10:20 am
Tags:
Orexigen, earnings
Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed
Seeking Alpha
Mon, 06/22/15 - 12:49 pm
Tags:
Orexigen, Contrave, obesity, Arena Pharmaceuticals, Vivus
Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap
Fierce Pharma Marketing
Mon, 06/8/15 - 12:13 pm
Tags:
obesity, Takeda, Contrave, Orexigen, Vivus, Qsymia, Eisai, Belviq, Arena Pharmaceuticals

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.